289 related articles for article (PubMed ID: 12426516)
21. Erythromycin breath test and clinical transplantation.
Watkins PB
Ther Drug Monit; 1996 Aug; 18(4):368-71. PubMed ID: 8857552
[TBL] [Abstract][Full Text] [Related]
22. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions.
Kharasch ED; Russell M; Mautz D; Thummel KE; Kunze KL; Bowdle A; Cox K
Anesthesiology; 1997 Jul; 87(1):36-50. PubMed ID: 9232132
[TBL] [Abstract][Full Text] [Related]
23. Effect of multiple doses of rifampin on the [14C N-methyl] erythromycin breath test in healthy male volunteers.
Gharaibeh MN; Gillen LP; Osborne B; Schwartz JI; Waldman SA
J Clin Pharmacol; 1998 Jun; 38(6):492-5. PubMed ID: 9650537
[TBL] [Abstract][Full Text] [Related]
24. Variability in activity of hepatic CYP3A4 in patients infected with HIV.
Slain D; Pakyz A; Israel DS; Monroe S; Polk RE
Pharmacotherapy; 2000 Aug; 20(8):898-907. PubMed ID: 10939550
[TBL] [Abstract][Full Text] [Related]
25. Steady-state pharmacokinetics of delavirdine in HIV-positive patients: effect on erythromycin breath test.
Cheng CL; Smith DE; Carver PL; Cox SR; Watkins PB; Blake DS; Kauffman CA; Meyer KM; Amidon GL; Stetson PL
Clin Pharmacol Ther; 1997 May; 61(5):531-43. PubMed ID: 9164415
[TBL] [Abstract][Full Text] [Related]
26. 13C-erythromycin breath test as a noninvasive measure of CYP3A activity in newborn infants: a pilot study.
de Wildt SN; Berns MJ; van den Anker JN
Ther Drug Monit; 2007 Apr; 29(2):225-30. PubMed ID: 17417078
[TBL] [Abstract][Full Text] [Related]
27. Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.
Kharasch ED; Whittington D; Hoffer C; Krudys K; Craig K; Vicini P; Sheffels P; Lalovic B
Clin Pharmacokinet; 2005; 44(7):731-51. PubMed ID: 15966756
[TBL] [Abstract][Full Text] [Related]
28. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects.
Mueck W; Kubitza D; Becka M
Br J Clin Pharmacol; 2013 Sep; 76(3):455-66. PubMed ID: 23305158
[TBL] [Abstract][Full Text] [Related]
29. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin.
Niemi M; Kivistö KT; Diczfalusy U; Bodin K; Bertilsson L; Fromm MF; Eichelbaum M
Pharmacogenet Genomics; 2006 Aug; 16(8):565-8. PubMed ID: 16847425
[TBL] [Abstract][Full Text] [Related]
30. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Mathijssen RH; de Jong FA; van Schaik RH; Lepper ER; Friberg LE; Rietveld T; de Bruijn P; Graveland WJ; Figg WD; Verweij J; Sparreboom A
J Natl Cancer Inst; 2004 Nov; 96(21):1585-92. PubMed ID: 15523087
[TBL] [Abstract][Full Text] [Related]
31. Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics.
Gashaw I; Kirchheiner J; Goldammer M; Bauer S; Seidemann J; Zoller K; Mrozikiewicz PM; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Nov; 74(5):448-57. PubMed ID: 14586385
[TBL] [Abstract][Full Text] [Related]
32. Effect of mibefradil on CYP3A4 in vivo.
Veronese ML; Gillen LP; Dorval EP; Hauck WW; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Oct; 43(10):1091-100. PubMed ID: 14517191
[TBL] [Abstract][Full Text] [Related]
33. Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.
Floyd MD; Gervasini G; Masica AL; Mayo G; George AL; Bhat K; Kim RB; Wilkinson GR
Pharmacogenetics; 2003 Oct; 13(10):595-606. PubMed ID: 14515058
[TBL] [Abstract][Full Text] [Related]
34. Comparative CYP3A4 inhibitory effects of venlafaxine, fluoxetine, sertraline, and nefazodone in healthy volunteers.
DeVane CL; Donovan JL; Liston HL; Markowitz JS; Cheng KT; Risch SC; Willard L
J Clin Psychopharmacol; 2004 Feb; 24(1):4-10. PubMed ID: 14709940
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test.
Michael M; Cullinane C; Hatzimihalis A; O'Kane C; Milner A; Booth R; Schlicht S; Clarke SJ; Francis P
Cancer Chemother Pharmacol; 2012 Jan; 69(1):125-35. PubMed ID: 21626050
[TBL] [Abstract][Full Text] [Related]
36. Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.
Parasrampuria DA; Mendell J; Shi M; Matsushima N; Zahir H; Truitt K
Br J Clin Pharmacol; 2016 Dec; 82(6):1591-1600. PubMed ID: 27530188
[TBL] [Abstract][Full Text] [Related]
37. Guidance for Rifampin and Midazolam Dosing Protocols To Study Intestinal and Hepatic Cytochrome P450 (CYP) 3A4 Induction and De-induction.
Kapetas AJ; Sorich MJ; Rodrigues AD; Rowland A
AAPS J; 2019 Jun; 21(5):78. PubMed ID: 31218462
[TBL] [Abstract][Full Text] [Related]
38. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.
Lown KS; Mayo RR; Leichtman AB; Hsiao HL; Turgeon DK; Schmiedlin-Ren P; Brown MB; Guo W; Rossi SJ; Benet LZ; Watkins PB
Clin Pharmacol Ther; 1997 Sep; 62(3):248-60. PubMed ID: 9333100
[TBL] [Abstract][Full Text] [Related]
39. Cytochrome P450 3A4 activity after surgical stress.
Haas CE; Kaufman DC; Jones CE; Burstein AH; Reiss W
Crit Care Med; 2003 May; 31(5):1338-46. PubMed ID: 12771600
[TBL] [Abstract][Full Text] [Related]
40. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
